European Council Backs Mini-Me Alzheimer Research
The EIC selected a Greek-led consortium to develop circular mini-proteins targeting protein-misfolding diseases.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Should governments prioritize funding for experimental AI-driven medical research?
The European Innovation Council has awarded funding to the Mini-Me project, an initiative aiming to treat protein-misfolding conditions like Alzheimer's. The project will leverage artificial intelligence to optimize therapeutic mini-proteins.
Why it matters
By targeting the accumulation of toxic proteins, this research seeks to address the root causes of neurodegenerative diseases. The grant provides essential support for developing therapies that restore memory and cognitive function.
The Mini-Me project consortium includes eight partners across six countries. Successful projects under this EIC programme can receive maximum grants of up to €4 million.
The players
European Innovation Council
This body manages EU funding programs designed to identify and support breakthrough scientific research and innovation.
Biomedical Sciences Research Centre Alexander Fleming
This Greek research institution serves as the lead coordinator for the Mini-Me project consortium.
ResQ Biotech
This biotechnology firm acts as the primary commercialisation partner for the development of therapeutic mini-proteins.
The details
The project combines the creation of billions of molecular variants with an AI-driven platform to refine therapeutic candidates. Preclinical studies have already demonstrated that the RSQ-020 candidate can restore learning and memory in animal models by inhibiting Tau aggregation.
Timeline
October 21, 2026: The research project funding was publicly reported.
The Big Picture
The Mini-Me project follows a pattern set by the EIC Pathfinder Open programme of funding high-risk, high-gain scientific research. It represents a shift toward using artificial intelligence to solve complex biological puzzles that were previously unmanageable.
The research focuses on potential future treatments that could target the biological mechanisms underlying Alzheimer's symptoms. While these findings are currently in the preclinical stage, they aim to offer new medical alternatives for long-term neurodegenerative care.
The takeaway
This funding underscores the growing importance of combining AI-driven molecular engineering with protein-based therapeutics in the fight against neurodegeneration. Ongoing advancements in these platforms remain a primary focus for long-term neurological health outcomes.
Further reading
Learn more about ongoing developments in the field by visiting the Alzheimer’s section.
Source note: This article includes information reported by Greek City Times.
Live Poll
Should governments prioritize funding for experimental AI-driven medical research?
